Announcements

1 November 2023
MDPI Insights: The CEO's Letter #5 - OA Week, UK, and Strategy

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Open Access Week 2023 – the Global Drive to Open Continues

As the world's largest open-access (OA) publisher, we believe that unrestricted access to research findings is the cornerstone of transparency, efficiency, and quality control across scientific disciplines. At MDPI, we provide free, immediate access to scientific papers, empowering scientists to examine, validate, replicate, and build upon existing results. This minimizes redundancy, optimizes resources, and fosters innovative approaches.

International OA Week, held from 23 to 29 October 2023, provided a unique opportunity to link the global movement toward open sharing and open science with the progress of policy changes at the local level. Our mission, during OA Week and all the year round, is to offer educational resources highlighting the benefits of open-access publishing. The MDPI Blog is a valuable resource for information on open access and open science.

Core principles of OA publishing

Accessibility, transparency, and collaboration are core principles of OA publishing. OA aims to break down barriers that have traditionally restricted research access, ensuring that knowledge is available to all, regardless of financial situation or institutional affiliations. Our commitment to diverse pathways for OA publishing worldwide includes discounts for researchers. You can learn more about how MDPI supports scientific communities here.

One of the key strengths of OA publishing is its ability to facilitate interdisciplinary research. By removing paywalls and promoting knowledge-sharing across disciplines, OA encourages collaboration and innovation. Researchers from various fields can access and build upon each others’ work, fostering a holistic approach to addressing complex global challenges.

OA holds the potential to democratize knowledge, advance science, and drive positive societal change.

Policy driving change

Governments, institutions, and funding agencies have recognized the transformative potential of OA and have implemented policies to promote it. These policies often require publicly funded research to be made openly accessible, accelerating the growth of OA repositories and journals. Check out our spotlights on OA policies in the USEU and China

OA publishing is continuously evolving, with community-driven models and technologies shaping its future. Initiatives such as “Plan S” and “cOAlition S” promote OA publishing from the perspective of national funders, requiring grantees to publish their research openly. A new policy announced by the US administration last year mandates that, with effect from January 2026, all US federally funded research should be freely and immediately available after publication.

Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing.

For more than two decades, OA publishing has been revolutionizing academic publishing by promoting accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As OA continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change.

MDPI is proud to lead the transition to open access.

Read more:

Impactful Research

Spotlight on Smart Cities

Smart cities will serve as a cornerstone for future human development. Their implementation will help us tackle many of the significant challenges we are facing – climate change, ageing populations, waste management, public safety, travel, and so on. Recognising the importance of this multifaceted field, MDPI launched the inaugural issue of Smart Cities in 2018 to provide an advanced forum for research into smart technology and society. Here we take a look at how this journal has developed, and its impact in this exciting field.

As at 30 October, 2023, Smart Cities has published 421 papers and has an Impact Factor of 6.4. It also has a CiteScore of 8.5, and more than one quarter of its published papers – 124 – have been cited 10 times or more.

Highly cited papers in Smart Cities

Below are several highly cited papers recently published in Smart Cities. Citation metrics are current as at 31 October 2023.

1. “Introducing the “15-Minute City”: Sustainability, Resilience and Place Identity in Future Post-Pandemic Cities
Authors: Carlos Moreno, Zaheer Allam, Didier Chabaud, Catherine Gall and Florent Pratlong
Smart Cities 2021, 4(1), 93-111; https://doi.org/10.3390/smartcities4010006
Citations: Crossref (338), Scopus (366), Web of Science (270), Google Scholar (710)
The paper discusses the socio-economic impacts of the COVID-19 on cities, including increasing inequalities and rising unemployment. It introduces the concept of the "15-Minute City," a form of "chrono-urbanism," as a response to the challenges posed by the pandemic.

2. “A Review on Electric Vehicles: Technologies and Challenges
Authors: Julio A. Sanguesa, Vicente Torres-Sanz, Piedad Garrido, Francisco J. Martinez and Johann M. Marquez-Barja
Smart Cities 2021, 4(1), 372-404; https://doi.org/10.3390/smartcities4010022
Citations: Crossref (359), Scopus (363), Web of Science (268), Google Scholar (558)
This paper provides an overview of the progress in Electric Vehicles (EVs), focusing on battery technology, charging methods, and emerging research challenges. It also analyzes the global EV market and its future outlook.

3. “IoT in Smart Cities: A Survey of Technologies, Practices and Challenges
Authors: Abbas Shah Syed, Daniel Sierra-Sosa, Anup Kumar and Adel Elmaghraby
Smart Cities 2021, 4(2), 429-475; https://doi.org/10.3390/smartcities4020024
Citations: Crossref (121), Scopus (151), Web of Science (91), Google Scholar (215)
This paper gives an overview of the Internet of Things (IoT) in the context of Smart Cities, discussing the fundamental components, technologies, architectures, networking technologies, and artificial algorithms that underpin IoT-based Smart City systems.

4. “Artificial Intelligence Techniques in Smart Grid: A Survey
Authors: Olufemi A. Omitaomu and Haoran Niu
Smart Cities 2021, 4(2), 548-568; https://doi.org/10.3390/smartcities4020029
Citations: Crossref (76), Scopus (94), Web of Science (57), Google Scholar (120)
This survey paper reviews the utilization of artificial intelligence (AI) techniques in the context of the smart grid. It covers various applications of AI in load forecasting, power grid stability assessment, fault detection, and security issues in the smart grid and power systems.

5. “The Metaverse as a Virtual Form of Smart Cities: Opportunities and Challenges for Environmental, Economic, and Social Sustainability in Urban Futures
Authors: Zaheer Allam, Ayyoob Sharifi, Simon Elias Bibri, David Sydney Jones and John Krogstie
Smart Cities 2022, 5(3), 771-801; https://doi.org/10.3390/smartcities5030040
Citations: Crossref (72), Scopus (75), Web of Science (43), Google Scholar (176)
This paper discusses the concept of the Metaverse, a virtual world introduced by Meta (formerly Facebook), and its potential impact on urban life. It explores how emerging technologies such as AI, Big Data, IoT, and Digital Twins could reshape urban design and services in the context of the Metaverse.

Testimonial

“It was indeed a great and pleasant experience with MDPI regarding our recent publication. The submission process was very straightforward and less time-consuming than the norm. The review process was very fast compared to many other open access journals, which is praiseworthy. The support from the Editorial Office during the revision process was highly useful as well. We look forward to publishing with MDPI in the future, and I will most definitely recommend MDPI to my colleagues and collaborators. – Dr. Luís Rosa, University of Minho

Article in Smart Cities: Mobile Networks and Internet of Things Infrastructures to Characterize Smart Human Mobility

Inside MDPI

MDPI Manchester office, UK Visit


Allie Shi (Editorial Director, MDPI), Stefan Tochev (CEO, MDPI), Jamie Anderson (Manchester Office Manager, MDPI), Michael O’Sullivan (Senior Scientific Officer, MDPI), Hushneara Akhtar, and Becky Castellon (IOAP Team Lead, MDPI), dining out in Manchester, UK.

In October, I visited MDPI’s new office in Manchester. During the visit, I connected with our English Editing (EE) managers, Scientific Officer, members of the Editorial team, the Marketing team, and IOAP Team Lead.

Our Manchester office focuses primarily on EE services and provides local support for the UK market. Additionally, we regularly visit Editorial Board members and participate in local conferences.

I would like to thank Jamie Anderson, Manchester Office Manager, and her team, for their deep commitment to our Manchester staff and to MDPI’s impact on the UK market.

The UK by numbers

The UK is a hub for the world’s top universities, making it a key market for MDPI and the publishing world in general. It is home to two of the top-five-ranked universities globally, 11 in the top 100, and 15 in the top 200.

As a result, the UK plays a key role in MDPI’s global market. As at October 2023, it ranks as the seventh-largest contributor to the total number of papers published by MDPI. We have 3,500 Editorial Board members affiliated with UK institutions, including 34 serving as Editors-in-Chief (EiCs). Our commitment to collaboration with institutions is evident in the UK, where we have successfully established some 60 Institutional Open Access Program (IOAP) agreements with esteemed institutions, such as the University of Oxford, the University of Cambridge, Imperial College London, the University of Edinburgh, and more.

According to InCites Dataset + ESCI for the period 2018–2022, as at October 2023, nearly 65% of UK papers are now published as OA. Just over 10% of total OA publications are by UK authors. UK papers are known for their high quality, with an average of 11 citations per paper. Furthermore, 2.16% of UK papers are in the top 1% of cited papers, and 14.61% are in the top 10% of cited papers, showcasing their impact.

We are currently hiring EEs in various locations worldwide.

English Editing at MDPI

Our English Editing (EE) department consists of two main branches, Quality Control and Learning and Development, reflecting our priorities. We are continuously enhancing the quality of our English Editing services and have raised the relevant standards, which now extend to company-wide communications. English editors participate in international interviews, conduct English assessments, and provide colleagues with presentations on ways to improve their use of written and spoken English.

While expanding, the EE department has proactively refocused its efforts on the quality of our work and how the English Editing department can benefit the company more broadly. We currently have approximately 140 full-time English Editors based across five offices worldwide, supplemented by over 700 freelance English editors.

Our Manchester office serves as the hub for the EE Department, with EE Managers situated there, except for Kurtis Jackson, who serves as the Head of EE and is located in our Basel office. Manchester EEs play a critical role in establishing and developing EE teams in our other offices, overseeing management and recruitment. The EE department plays a vital role in MDPI’s operations, as it is the department that touches every published paper. If this work interests you, I encourage you to explore our available EE positions, whether you are seeking full-time or freelance opportunities.

Testimonials

“MDPI provides an excellent service compared to any other previously used services. It delivers fast and high-quality results but at an affordable price.” – Ardha Apriyanto, University of Potsdam

“In my role as a professor, I consider that MDPI Author Services offer an excellent quality in the editing of Western academic writing while maintaining the required standards of clarity, precision and rigor. Additionally, delivery times are fast compared to other available services.” – Jesus Insuasti, University of Nariño

Read more:

Coming Together for Science

STM and Frankfurt Book Fair

Attending STM

MDPI has been a proud sponsor of the STM Conference for several years. The STM Conference is a dynamic event featuring interactive sessions, expert panellists, idea-sharing, and ample networking opportunities. On 16 October, the event kicked off with arrival drinks, sponsored by MDPI, followed by a welcoming dinner, providing a great chance to connect and network with industry professionals. The following day was filled with speakers, sessions, and further opportunities to connect. STM exemplifies the collaborative spirit of the scientific community, with session topics including achieving open, visible, and impactful research at scale; maintaining research integrity in a rapidly changing world; and exploring the impact of ever-evolving technology in the scholarly community.

Meeting with Web of Science

On a personal note, one of the highlights of STM was a candid and productive conversation with Nandita Quaderi, Editor-in-Chief and SVP at Web of Science. During our discussion, we talked about MDPI, Web of Science, the IJERPH delisting, and ways of moving forward. This open conversation aimed at fostering better collaboration for the future.

“We discussed ways to improve our communication and collaboration.”

I appreciated our frank discussion and felt that Nandita wholeheartedly supports open access. She also expressed her appreciation for the monthly CEO Letter, which she sees as a way to add personality to the MDPI brand and provide insight into the great work we do at MDPI. While we highlighted the positives, we also discussed ways to improve our communication and collaboration moving forward. This meeting alone made the trip worthwhile, and I hope Nandita doesn’t mind my sharing that she found our chat to be “the most honest and constructive discussion” she’s had with someone from MDPI in recent years.

75th Frankfurt Book Fair


Jelena Milojevic (Book Editor, MDPI), Jovana Dubajic (Book Editor, MDPI), Evan Escamilla (Project Manager, MDPI), Laura Wagner (Head of Books, MDPI), and Jenny Knowles (Commissioning Editor, MDPI), at the Frankfurt Book Fair in Frankfurt am Main, Germany.

For the 75th time, the Frankfurter Buchmesse opened its doors in October to celebrate exciting stories and their authors. If you haven’t yet had the chance to visit the Frankfurt Book Fair, I highly recommend it. It’s the largest book fair in the world, attracting thousands of visitors from around the globe. This is the place to gain valuable industry insights from top-class publishing professionals, connect with publishers directly, and learn about the latest trends in publishing.

MDPI Books

Our Books team was also present at the Frankfurt Book Fair, networking and learning from various panels. Did you know that our MDPI Books department publishes OA Books?

The book publishing program includes monographs, book series, edited books and reprints of special issues and topical collections, among other book types.

If you have a book proposal you would like to discuss, please feel free to contact our Books team to understand the benefits and methods of publishing your next book with the OA model.

Closing Thoughts

MDPI Strategy Meeting

As the newly appointed CEO, this is my first year leading the MDPI Senior Management Strategy session. I saw it as an opportunity to explore what MDPI has the potential to become in the next five years. Guided by the vision of its founder and President, Dr. Shu-kun Lin, the company has accomplished remarkable feats over the past 27 years and currently holds the position as the world’s third-largest academic publisher, following Springer Nature and Elsevier.

Our primary objective is to build upon the milestones of the past decades and consolidate MDPI’s position as well-established publishing brand. The two-day meeting emphasized the importance of communicating MDPI’s values more actively via its brand and adopting a straightforward yet impactful approach to managing MDPI as a mature academic publisher.

“Our primary objective is to consolidate MDPI’s position as well-established publishing brand”

As the world’s number one open-access publisher, MDPI has long been a game-changer in the scholarly community, serving millions of authors. The challenge in being a trailblazer is the need to continuously improve and at the same time explore the next blue-ocean strategy, while also maintaining the smooth operation of the business. Our collection model, featuring guest-curated thematic topics in the form of Special Issues, has disrupted the industry. Other publishers closely study us and attempt to replicate our models. The future of this collection model is something we are actively addressing – while, of course, looking ahead to what comes next!

Stefan Tochev
Chief Executive Officer
MDPI AG

25 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Bone and Soft Tissue Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Bone and Soft Tissue Oncology” listed below:

1. “Synovial Sarcoma: A Clinical Review”
by Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(3), 1909–1920; https://doi.org/10.3390/curroncol28030177
Available online: https://www.mdpi.com/1718-7729/28/3/177

2. “Current Overview of Treatment for Metastatic Bone Disease”
by Shinji Tsukamoto, Akira Kido, Yasuhito Tanaka, Giancarlo Facchini, Giuliano Peta, Giuseppe Rossi and Andreas F. Mavrogenis
Curr. Oncol. 2021, 28(5), 3347–3372; https://doi.org/10.3390/curroncol28050290
Available online: https://www.mdpi.com/1718-7729/28/5/290

3. “Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease”
by Aaron Gazendam, Daniel Axelrod, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(4), 2731–2740; https://doi.org/10.3390/curroncol28040238
Available online: https://www.mdpi.com/1718-7729/28/4/238

4. “The Role of a Navigational Radiofrequency Ablation Device and Concurrent Vertebral Augmentation for Treatment of Difficult-to-Reach Spinal Metastases”
by Claudio Pusceddu, Davide De Francesco, Luca Melis, Nicola Ballicu and Alessandro Fancellu
Curr. Oncol. 2021, 28(5), 4004–4015; https://doi.org/10.3390/curroncol28050340
Available online: https://www.mdpi.com/1718-7729/28/5/340

5. “The Surgical Management of Proximal Femoral Metastases: A Narrative Review”
by Daniel Axelrod, Aaron M. Gazendam and Michelle Ghert
Curr. Oncol. 2021, 28(5), 3748–3757; https://doi.org/10.3390/curroncol28050320
Available online: https://www.mdpi.com/1718-7729/28/5/320

6. “We’re on a Merry-Go-Round”: Reflections of Patients and Carers after Completing Treatment for Sarcoma”
by Rhys Weaver, Moira O’Connor, Richard Carey Smith, Dianne Sheppard and Georgia K. B. Halkett
Curr. Oncol. 2021, 28(4), 3003–3014; https://doi.org/10.3390/curroncol28040263
Available online: https://www.mdpi.com/1718-7729/28/4/263

7. “Assessment of Risk of Bias in Osteosarcoma and Ewing’s Sarcoma Randomized Controlled Trials: A Systematic Review”
by Robert Koucheki, Aaron M. Gazendam, Jonathan R. Perera, Anthony Griffin, Peter Ferguson, Jay Wunder and Kim Tsoi
Curr. Oncol. 2021, 28(5), 3771–3794; https://doi.org/10.3390/curroncol28050322
Available online: https://www.mdpi.com/1718-7729/28/5/322

8. “Impact of an Augmented Reality Navigation System (SIRIO) on Bone Percutaneous Procedures: A Comparative Analysis with Standard CT-Guided Technique”
by Eliodoro Faiella, Gennaro Castiello, Caterina Bernetti, Giuseppina Pacella, Carlo Altomare, Flavio Andresciani, Bruno Beomonte Zobel and Rosario Francesco Grasso
Curr. Oncol. 2021, 28(3), 1751–1760; https://doi.org/10.3390/curroncol28030163
Available online: https://www.mdpi.com/1718-7729/28/3/163

9. “Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report”
by Thierry Alcindor, Sungmi Jung and Lucy Gilbert
Curr. Oncol. 2021, 28(3), 2146–2149; https://doi.org/10.3390/curroncol28030199
Available online: https://www.mdpi.com/1718-7729/28/3/199

10. “The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review”
by Abha Gupta, Lisa Durocher-Allen, Snezana Popovic, Richard Tozer, Xiaomei Yao and Michelle Ghert
Curr. Oncol. 2021, 28(2), 1302–1313; https://doi.org/10.3390/curroncol28020124
Available online: https://www.mdpi.com/1718-7729/28/2/124

24 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Breast Cancer”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Breast Cancer” listed below:

1. “Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors”
by Sonu S. Varghese, Will J. Johnston, Cameron R. Eekhoudt, Melanie R. Keats, Davinder S. Jassal and Scott A. Grandy
Curr. Oncol. 2021, 28(5), 4139–4156; https://doi.org/10.3390/curroncol28050351
Available online: https://www.mdpi.com/1718-7729/28/5/351

2. “Comparison of the Quality of Life of Patients with Breast or Colon Cancer with an Arm Vein Port (TIVAD) Versus a Peripherally Inserted Central Catheter (PICC)”
by Brent Burbridge, Hyun Lim, Lynn Dwernychuk, Ha Le, Tehmina Asif, Amer Sami and Shahid Ahmed
Curr. Oncol. 2021, 28(2), 1495–1506; https://doi.org/10.3390/curroncol28020141
Available online: https://www.mdpi.com/1718-7729/28/2/141

3. “The Challenge of Return to Work after Breast Cancer: The Role of Family Situation, CANTO Cohort”
by Elsa Caumette, Inès Vaz-Luis, Sandrine Pinto, Julie Havas, Thomas Bovagnet, Garazi Ruiz de Azua, Antonio Di Meglio, Anne-Laure Martin, Sibille Everhard, Paul Cottu et al.
Curr. Oncol. 2021, 28(5), 3866–3875; https://doi.org/10.3390/curroncol28050330
Available online: https://www.mdpi.com/1718-7729/28/5/330

4. “A Multidisciplinary Approach to Implement Personalized Breast Cancer Treatment and Care Plans”
by Rashida Haq, Amy Kong and Pauline Gulasingam
Curr. Oncol. 2021, 28(1), 767–782; https://doi.org/10.3390/curroncol28010075
Available online: https://www.mdpi.com/1718-7729/28/1/75

5. “Longitudinal Symptom Burden Trajectories in a Population-Based Cohort of Women with Metastatic Breast Cancer: A Group-Based Trajectory Modeling Analysis”
by Suman Budhwani, Rahim Moineddin, Walter P. Wodchis, Camilla Zimmermann and Doris Howell
Curr. Oncol. 2021, 28(1), 879–897; https://doi.org/10.3390/curroncol28010087
Available online: https://www.mdpi.com/1718-7729/28/1/87

6. “Cancer-Specific Outcomes in the Elderly with Triple-Negative Breast Cancer: A Systematic Review”
by Jenny Yoon, Gregory Knapp, May Lynn Quan and Antoine Bouchard-Fortier
Curr. Oncol. 2021, 28(4), 2337–2345; https://doi.org/10.3390/curroncol28040215
Available online: https://www.mdpi.com/1718-7729/28/4/215

7. “Narratives of Survivorship: A Study of Breast Cancer Pathographies and Their Place in Cancer Rehabilitation”
by Åsa Mohlin and Katarina Bernhardsson
Curr. Oncol. 2021, 28(4), 2840–2851; https://doi.org/10.3390/curroncol28040249
Available online: https://www.mdpi.com/1718-7729/28/4/249

8. “Factors Associated with “Survivor Identity” in Men with Breast Cancer”
by Kathryn L. Dalton, Sheila N. Garland, Peggy Miller, Bret Miller, Cheri Ambrose and Richard J. Wassersug
Curr. Oncol. 2021, 28(3), 1696–1705; https://doi.org/10.3390/curroncol28030158
Available online: https://www.mdpi.com/1718-7729/28/3/158 

9. “Results from a Theory-Guided Survey to Support Breast Cancer Trial Participation: Barriers, Enablers, and What to Do about them”
by Jamie C. Brehaut, Kelly Carroll, Jenn Gordon, Justin Presseau, Dawn P. Richards, Dean A. Fergusson, Ian D. Graham and Susan Marlin
Curr. Oncol. 2021, 28(3), 2014–2028; https://doi.org/10.3390/curroncol28030187
Available online: https://www.mdpi.com/1718-7729/28/3/187

10. “Acute Care Use by Breast Cancer Patients on Adjuvant Chemotherapy in Alberta: Demonstrating the Importance of Measurement to Improving Quality”
by Che Hsuan David Wu, May Lynn Quan, Shiying Kong, Yuan Xu, Jeffrey Q. Cao, Sasha Lupichuk and Lisa Barbera
Curr. Oncol. 2021, 28(6), 4420–4431; https://doi.org/10.3390/curroncol28060375
Available online: https://www.mdpi.com/1718-7729/28/6/375

24 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Gastrointestinal Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Gastrointestinal Oncology” listed below:

1. “Artificial Intelligence in Colorectal Cancer Screening, Diagnosis and Treatment. A New Era”
by Athanasia Mitsala, Christos Tsalikidis, Michail Pitiakoudis, Constantinos Simopoulos and Alexandra K. Tsaroucha
Curr. Oncol. 2021, 28(3), 1581–1607; https://doi.org/10.3390/curroncol28030149
Available online: https://www.mdpi.com/1718-7729/28/3/149

2. “Pathological Features and Prognostication in Colorectal Cancer”
by Kabytto Chen, Geoffrey Collins, Henry Wang and James Wei Tatt Toh
Curr. Oncol. 2021, 28(6), 5356–5383; https://doi.org/10.3390/curroncol28060447
Available online: https://www.mdpi.com/1718-7729/28/6/447

3. “Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma”
by Yuji Eso, Haruhiko Takeda, Kojiro Taura, Atsushi Takai, Ken Takahashi and Hiroshi Seno
Curr. Oncol. 2021, 28(5), 4157–4166; https://doi.org/10.3390/curroncol28050352
Available online: https://www.mdpi.com/1718-7729/28/5/352

4. “Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma”
by Silvia Gaia, Michela Ciruolo, Davide Giuseppe Ribaldone, Emanuela Rolle, Enrica Migliore, Elena Mosso, Simone Vola, Alessandra Risso, Sharmila Fagoonee, Giorgio Maria Saracco et al.
Curr. Oncol. 2021, 28(2), 1034–1044; https://doi.org/10.3390/curroncol28020101
Available online: https://www.mdpi.com/1718-7729/28/2/101

5. “Screening for Colorectal Cancer Leading into a New Decade: The “Roaring ‘20s” for Epigenetic Biomarkers?”
by Hélder Almeida-Lousada, André Mestre, Sara Ramalhete, Aryeh J. Price, Ramon Andrade de Mello, Ana D. Marreiros, Ricardo Pires das Neves and Pedro Castelo-Branco
Curr. Oncol. 2021, 28(6), 4874–4893; https://doi.org/10.3390/curroncol28060411
Available online: https://www.mdpi.com/1718-7729/28/6/411

6. “Geographic and Socioeconomic Disparity of Gastric Cancer Patients in Canada”
by Leila Cattelan, Feras M. Ghazawi, Michelle Le, François Lagacé, Elham Rahme, Andrei Zubarev, Denis Sasseville, Ivan V. Litvinov, Kevin A. Waschke and Elena Netchiporouk
Curr. Oncol. 2021, 28(3), 2052–2064; https://doi.org/10.3390/curroncol28030190
Available online: https://www.mdpi.com/1718-7729/28/3/190

7. “Quality of Colon Cancer Care in Patients Undergoing Emergency Surgery”
by Keegan Guidolin, Rebecca Withers, Farhana Shariff, Shady Ashamalla and Ashlie Nadler
Curr. Oncol. 2021, 28(3), 2079–2086; https://doi.org/10.3390/curroncol28030192
Available online: https://www.mdpi.com/1718-7729/28/3/192

8. “Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms—A Single-Center Retrospective Outcome Analysis”
by Kirsten Lindner, Daniel Binte, Jens Hoeppner, Ulrich F. Wellner, Dominik M. Schulte, Sebastian M. Schmid, Kim Luley, Inga Buchmann, Lars Tharun, Tobias Keck et al.
Curr. Oncol. 2021, 28(4), 3071–3080; https://doi.org/10.3390/curroncol28040268
Available online: https://www.mdpi.com/1718-7729/28/4/268

9. “The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis”
by Suganija Lakkunarajah, Daniel A. Breadner, Hanbo Zhang, Ellen Yamanaka, Andrew Warner and Stephen Welch
Curr. Oncol. 2021, 28(5), 4031–4041; https://doi.org/10.3390/curroncol28050342
Available online: https://www.mdpi.com/1718-7729/28/5/342

10. “Recent Advances in Photodynamic Imaging and Therapy in Hepatobiliary Malignancies: Clinical and Experimental Aspects”
by Atsushi Nanashima, Masahide Hiyoshi, Naoya Imamura, Koichi Yano, Takeomi Hamada and Kengo Kai
Curr. Oncol. 2021, 28(5), 4067–4079; https://doi.org/10.3390/curroncol28050345
Available online: https://www.mdpi.com/1718-7729/28/5/345

23 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Genitourinary Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Genitourinary Oncology” listed below:

1. “Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making”
by Philipp Mandel, Mike Wenzel, Benedikt Hoeh, Maria N. Welte, Felix Preisser, Tahir Inam, Clarissa Wittler, Clara Humke, Jens Köllermann, Peter Wild et al.
Curr. Oncol. 2021, 28(3), 2123–2133; https://doi.org/10.3390/curroncol28030197
Available online: https://www.mdpi.com/1718-7729/28/3/197

2. “Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy”
by Benedikt Hoeh, Felix Preisser, Mike Wenzel, Clara Humke, Clarissa Wittler, Jan L. Hohenhorst, Maja Volckmann-Wilde, Jens Köllermann, Thomas Steuber, Markus Graefen et al.
Curr. Oncol. 2021, 28(6), 4738–4747; https://doi.org/10.3390/curroncol28060399
Available online: https://doi.org/10.3390/curroncol28060399

3. “The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging”
by Daiki Kato, Kaori Ozawa, Shinichi Takeuchi, Makoto Kawase, Kota Kawase, Chie Nakai, Manabu Takai, Koji Iinuma, Keita Nakane, Hiroki Kato et al.
Curr. Oncol. 2021, 28(2), 1294–1301; https://doi.org/10.3390/curroncol28020123
Available online: https://www.mdpi.com/1718-7729/28/2/123

4. “Extreme Hypofractionation with SBRT in Localized Prostate Cancer”
by Maria Antonia Gómez-Aparicio, Jeannette Valero, Begoña Caballero, Rafael García, Ovidio Hernando-Requejo, Ángel Montero, Alfonso Gómez-Iturriaga, Thomas Zilli, Piet Ost, Fernando López-Campos, et al.
Curr. Oncol. 2021, 28(4), 2933–2949; https://doi.org/10.3390/curroncol28040257
Available online: https://www.mdpi.com/1718-7729/28/4/257

5. “Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases”
by Tomas Buchler, Lukas Fiser, Jaroslava Benesova, Hana Jirickova and Jana Votrubova
Curr. Oncol. 2021, 28(5), 3403–3407; https://doi.org/10.3390/curroncol28050294
Available online: https://www.mdpi.com/1718-7729/28/5/294

6. “Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells”
by Hyunho Kim, Okran Kim, Myung Ah Lee, Ji Youl Lee, Sung-Hoo Hong, U-Syn Ha, Kwangil Yim and In-Ho Kim
Curr. Oncol. 2021, 28(3), 1652–1662; https://doi.org/10.3390/curroncol28030154
Available online: https://www.mdpi.com/1718-7729/28/3/154

7. “Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)”
by Ibon Gurruchaga Sotés, Ana Nuño Alves, Sandra Vicente Arregui and Carmen Santander Lobera
Curr. Oncol. 2021, 28(4), 2346–2350; https://doi.org/10.3390/curroncol28040216
Available online: https://www.mdpi.com/1718-7729/28/4/216

8. “Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer”
by Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Michael Weber, Bernhard Grubmüller, Gero Kramer, Shahrokh F. Shariat, Markus Mitterhauser, Stefan Schmitl, Chrysoula Vraka et al.
Curr. Oncol. 2021, 28(5), 3692–3704; https://doi.org/10.3390/curroncol28050315
Available online: https://www.mdpi.com/1718-7729/28/5/315

9. “Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time”
by Okeroghene Ataikiru, Mahmoud Abdelsalam, Mrudula Avileli and Trina Hynes
Curr. Oncol. 2021, 28(6), 4291–4297; https://doi.org/10.3390/curroncol28060365
Available online: https://www.mdpi.com/1718-7729/28/6/365

10. “Cost–Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer”
by Najlaa Alyamani, Jiheon Song, Sasha van Katwyk, Kednapa Thavorn, Julie Renaud, Alain Haddad, Miller MacPherson and Marc Gaudet
Curr. Oncol. 2021, 28(4), 2385–2398; https://doi.org/10.3390/curroncol28040219
Available online: https://www.mdpi.com/1718-7729/28/4/219

20 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Childhood, Adolescent and Young Adult Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Childhood, Adolescent and Young Adult Oncology” listed below:

1. “A Cross-Sectional Survey Exploring the Impact of the COVID-19 Pandemic on the Cancer Care of Adolescents and Young Adults”
by Kaitlyn Howden, Camille Glidden, Razvan G. Romanescu, Andrew Hatala, Ian Scott, Julie Deleemans, Karine Chalifour, Geoff Eaton, Abha A. Gupta, James M. Bolton et al.
Curr. Oncol. 2021, 28(4), 3201–3213; https://doi.org/10.3390/curroncol28040278
Available online: https://www.mdpi.com/1718-7729/28/4/278

2. “The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors”
by Angelina Cistaro, Domenico Albano, Pierpaolo Alongi, Riccardo Laudicella, Daniele Antonio Pizzuto, Giuseppe Formica, Cinzia Romagnolo, Federica Stracuzzi, Viviana Frantellizzi, Arnoldo Piccardo et al.
Curr. Oncol. 2021, 28(4), 2481–2495; https://doi.org/10.3390/curroncol28040226
Available online: https://www.mdpi.com/1718-7729/28/4/226

3. “The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors”
by Julian Kolorz, Salih Demir, Adrian Gottschlich, Iris Beirith, Matthias Ilmer, Daniel Lüthy, Christoph Walz, Mario M. Dorostkar, Thomas Magg, Fabian Hauck et al.
Curr. Oncol. 2022, 29(1), 94–110; https://doi.org/10.3390/curroncol29010008
Available online: https://www.mdpi.com/1718-7729/29/1/8

4. “A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma”
by Stefano Testa, Benjamin D. Hu, Natalie L. Saadeh, Allison Pribnow, Sheri L. Spunt, Gregory W. Charville, Nam Q. Bui and Kristen N. Ganjoo
Curr. Oncol. 2021, 28(6), 5304–5317; https://doi.org/10.3390/curroncol28060443
Available online: https://www.mdpi.com/1718-7729/28/6/443

5. “Parents’ Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study”
by Étienne Camiré-Bernier, Erwan Nidelet, Amel Baghdadli, Gabriel Demers, Marie-Christine Boulanger, Marie-Claude Brisson, Bruno Michon, Sophie Lauzier and Isabelle Laverdière
Curr. Oncol. 2021, 28(6), 4377–4391; https://doi.org/10.3390/curroncol28060372
Available online: https://www.mdpi.com/1718-7729/28/6/372

20 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Health Economics”

As Current Oncology (ISSN: 1718-7729) is of an open-access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Health Economics” listed below:

1. “Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients”
by Yuti P. Patel, Donald Husereau, Natasha B. Leighl, Barbara Melosky and Julian Nam
Curr. Oncol. 2021, 28(6), 5278–5294; https://doi.org/10.3390/curroncol28060441
Available online: https://www.mdpi.com/1718-7729/28/6/441

2. “Cost Analysis of Laparoscopic Low Anterior Resection vs. Transanal Endoscopic Microsurgery for Rectal Neoplasms”
by Katerina Neumann, Nirmal Randhawa, Jason Park and David J. Hochman
Curr. Oncol. 2021, 28(3), 1795–1802; https://doi.org/10.3390/curroncol28030167
Available online: https://www.mdpi.com/1718-7729/28/3/167

3. “The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review”
by Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald and Beverley Essue
Curr. Oncol. 2021, 28(2), 1216–1248; https://doi.org/10.3390/curroncol28020117
Available online: https://www.mdpi.com/1718-7729/28/2/117

4. “Cost Minimization Analysis of Hypofractionated Radiotherapy”
by Hannah L.Yaremko, Gordon E. Locke, Ronald Chow, Michael Lock, Robert Dinniwell and Brian P. Yaremko
Curr. Oncol. 2021, 28(1), 716–725; https://doi.org/10.3390/curroncol28010070
Available online: https://www.mdpi.com/1718-7729/28/1/70

5. “Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care”
by Adam J. N. Raymakers, David Cameron, Scott Tyldesley and Dean A. Regier
Curr. Oncol. 2021, 28(3), 1857–1866; https://doi.org/10.3390/curroncol28030172
Available online: https://www.mdpi.com/1718-7729/28/3/172

6. “Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs”
by Ronak Saluja, Tina Jiao, Liza Koshy, Matthew Cheung and Kelvin K. W. Chan
Curr. Oncol. 2021, 28(1), 606–618; https://doi.org/10.3390/curroncol28010060
Available online: https://www.mdpi.com/1718-7729/28/1/60

7. “Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer”
by Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond et al.
Curr. Oncol. 2021, 28(3), 1847–1856; https://doi.org/10.3390/curroncol28030171
Available online: https://www.mdpi.com/1718-7729/28/3/171

8. “Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial”
by Anca Prica, Annette E. Hay, Michael Crump, Nicole Mittmann, Lois E. Shepherd, Ralph M. Meyer, Kevin I. Imrie, Nancy Risebrough, Marina Djurfeldt, Bingshu E. Chen et al.
Curr. Oncol. 2021, 28(2), 1256–1261; https://doi.org/10.3390/curroncol28020119
Available online: https://www.mdpi.com/1718-7729/28/2/119

19 October 2023
Open Access Week 2023 – the Global Drive to Open Continues


MDPI has been a strong proponent of the open access publishing model right from the beginning. As one of the pioneering fully open access publishers, we firmly believe that unrestricted access to research findings forms the foundation for better transparency, efficiency, and quality control across all scientific disciplines.

In December 2022, we reached a significant milestone by surpassing one million articles published. That is one million articles freely available to all, to circulate and build upon!

Offering free and immediate access to scientific papers empowers scientists to examine, validate, replicate, and expand upon existing results. This not only helps prevent redundancy and optimizes how resources are used but also paves the way for innovative new approaches.

The International Open Access Week takes place from 23 to 29 October 2023, providing a unique opportunity to connect the global movement towards open sharing and open science with the progress of policy transformations at the local level.

Our goal, during Open Access Week as well as throughout the year, is to offer resources for educating people about the benefits of open access publishing. The MDPI Blog offers a wealth of information around open access and open science.

Promoting the values of accessibility, transparency, and collaboration

Open access publishing embodies the fundamental values of democratizing knowledge and fostering global accessibility. It aims to break down barriers that have traditionally limited access to scholarly work, ensuring that knowledge is available to all, regardless of their financial or institutional affiliations. 

Discounts are part of our commitment to ensuring there are diverse pathways to Open Access publishing for researchers worldwide. MDPI supports scientific communities in several different ways. 

One of the key strengths of open access publishing lies in its ability to facilitate interdisciplinary research. By removing paywalls and promoting the sharing of knowledge across disciplines, OA encourages collaboration and innovation. Researchers from diverse fields can access and build upon each other's work, fostering a holistic approach to addressing complex global challenges. 

Funders' policies are getting aligned with open science

Governments, institutions, and funding agencies have recognized the transformative potential of open access and have implemented policies to promote it. These policies often mandate that publicly funded research should be made openly accessible. Such initiatives have accelerated the growth of open access repositories and journals, reinforcing the commitment to open access principles. Check our spotlights on OA policies in the USEU and China

Open access publishing is continually evolving, with innovative and community-driven models and technologies shaping its future. Initiatives like "Plan S" and "cOAlition S" promote the adoption of OA publishing from the national funders’ perspective by requiring grantees to publish their research openly. A new policy announced by the US administration last year requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication. 

Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing. 

For more than twenty years, open access scholarly publishing has been revolutionizing academia by promoting the values of accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As open access continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change. 

MDPI is proud to be a leader in the transition to open access.

19 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Thoracic Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Thoracic Oncology” listed below:

1. “The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review”
by Goulnar Kasymjanova, Aksa Anwar, Victor Cohen, Khalil Sultanem, Carmela Pepe, Lama Sakr, Jennifer Friedmann and Jason S. Agulnik
Curr. Oncol. 2021, 28(6), 4247–4255; https://doi.org/10.3390/curroncol28060360
Available online: https://www.mdpi.com/1718-7729/28/6/360

2. “Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada”
by Dylan E. O’Sullivan, Winson Y. Cheung, Iqra A. Syed, Daniel Moldaver, Mary Kate Shanahan, D. Gwyn Bebb, Christina Sit, Darren R. Brenner and Devon J. Boyne
Curr. Oncol. 2021, 28(4), 3091–3103; https://doi.org/10.3390/curroncol28040270
Available online: https://www.mdpi.com/1718-7729/28/4/270

3. “Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer—A Cost-Efficient Strategy in a Public Healthcare System”
by Maisam Makarem, Doreen A. Ezeife, Adam C. Smith, Janice J. N. Li, Jennifer H. Law, Ming-Sound Tsao and Natasha B. Leighl
Curr. Oncol. 2021, 28(5), 3268–3279; https://doi.org/10.3390/curroncol28050284
Available online: https://www.mdpi.com/1718-7729/28/5/284

4. “Immunotherapy in Extensive-Stage Small Cell Lung Cancer”
by Rola El Sayed, and Normand Blais
Curr. Oncol. 2021, 28(5), 4093–4108; https://doi.org/10.3390/curroncol28050347
Available online: https://www.mdpi.com/1718-7729/28/5/347

5. “Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database”
by Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb et al.
Curr. Oncol. 2021, 28(5), 4213–4222; https://doi.org/10.3390/curroncol28050357
Available online: https://www.mdpi.com/1718-7729/28/5/357

6. “Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer”
by Christopher Cao, Anthony Le, Matthew Bott, Chi-Fu Jeffrey Yang, Dominique Gossot, Franca Melfi, David H. Tian and Allen Guo
Curr. Oncol. 2021, 28(6), 4686–4701; https://doi.org/10.3390/curroncol28060395
Available online: https://www.mdpi.com/1718-7729/28/6/395

7. “Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes”
by Sarah Sharman Moser, Jair Bar, Inna Kan, Keren Ofek, Raanan Cohen, Nikhil Khandelwal, Varda Shalev, Gabriel Chodick and Nava Siegelmann-Danieli
Curr. Oncol. 2021, 28(1), 317–331; https://doi.org/10.3390/curroncol28010036
Available online: https://www.mdpi.com/1718-7729/28/1/36

8. “Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations”
by Constance Petiteau, Gwladys Robinet-Zimmermann, Adèle Riot, Marine Dorbeau, Nicolas Richard, Cécile Blanc-Fournier, Frédéric Bibeau, Simon Deshayes, Emmanuel Bergot, Radj Gervais et al.
Curr. Oncol. 2021, 28(6), 4432–4445; https://doi.org/10.3390/curroncol28060376
Available online: https://www.mdpi.com/1718-7729/28/6/376

9. “Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
by Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi and Hironori Sagara
Curr. Oncol. 2021, 28(2), 1094–1113; https://doi.org/10.3390/curroncol28020106
Available online: https://www.mdpi.com/1718-7729/28/2/106

10. “Health Resource and Cost Savings Achieved in a Multidisciplinary Lung Cancer Clinic”
by Christopher J. L. Stone, Ana P. Johnson, Danielle Robinson, Andriy Katyukha, Rylan Egan, Sophia Linton, Christopher Parker, Andrew Robinson and Geneviève C. Digby
Curr. Oncol. 2021, 28(3), 1681–1695; https://doi.org/10.3390/curroncol28030157
Available online: https://www.mdpi.com/1718-7729/28/3/157

18 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Surgical Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Surgical Oncology” listed below:

1. “Synovial Sarcoma: A Clinical Review”
by Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(3), 1909–1920; https://doi.org/10.3390/curroncol28030177
Available online: https://www.mdpi.com/1718-7729/28/3/177

2. “Combined Exoscopic and Endoscopic Technique for Craniofacial Resection”
by Kenichiro Iwami, Tadashi Watanabe, Koji Osuka, Tetsuya Ogawa, Shigeru Miyachi and Yasushi Fujimoto
Curr. Oncol. 2021, 28(5), 3945–3958; https://doi.org/10.3390/curroncol28050336
Available online: https://www.mdpi.com/1718-7729/28/5/336

3. “Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease”
by Aaron Gazendam, Daniel Axelrod, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(4), 2731–2740; https://doi.org/10.3390/curroncol28040238
Available online: https://www.mdpi.com/1718-7729/28/4/238

4. “The Surgical Management of Proximal Femoral Metastases: A Narrative Review”
by Daniel Axelrod, Aaron M. Gazendam and Michelle Ghert
Curr. Oncol. 2021, 28(5), 3748–3757; https://doi.org/10.3390/curroncol28050320
Available online: https://www.mdpi.com/1718-7729/28/5/320

5. “Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience”
by Shintaro Narita, Mitsuru Saito, Kazuyuki Numakura and Tomonori Habuchi
Curr. Oncol. 2021, 28(5), 4109–4117; https://doi.org/10.3390/curroncol28050348
Available online: https://www.mdpi.com/1718-7729/28/5/348

6. “The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review”
by Abha Gupta, Lisa Durocher-Allen, Snezana Popovic, Richard Tozer, Xiaomei Yao and Michelle Ghert
Curr. Oncol. 2021, 28(2), 1302–1313; https://doi.org/10.3390/curroncol28020124
Available online: https://www.mdpi.com/1718-7729/28/2/124

7. “Do Preoperative Transfusions Impact Prognosis in Moderate to Severe Anaemic Surgical Patients with Colon Cancer?”
by Nicolò Tamini, Luca Gianotti, Shadya Darwish, Salvatore Petitto, Davide Bernasconi, Massimo Oldani, Fabio Uggeri, Marco Braga and Luca Nespoli
Curr. Oncol. 2021, 28(6), 4634–4644; https://doi.org/10.3390/curroncol28060391
Available online: https://www.mdpi.com/1718-7729/28/6/391

8. “Salvage Surgical Resection after Linac-Based Stereotactic Radiosurgery for Newly Diagnosed Brain Metastasis”
by Ryosuke Matsuda, Takayuki Morimoto, Tetsuro Tamamoto, Nobuyoshi Inooka, Tomoko Ochi, Toshiteru Miyasaka, Shigeto Hontsu, Kaori Yamaki, Sachiko Miura, Yasuhiro Takeshima et al.
Curr. Oncol. 2021, 28(6), 5255–5265; https://doi.org/10.3390/curroncol28060439
Available online: https://www.mdpi.com/1718-7729/28/6/439

9. “National Variations in the Work-Up, Investigation, and Surgical Management of Ductal Carcinoma In Situ of the Breast across Canadian Surgeons”
by Ryerson Seguin and Lashan Peiris
Curr. Oncol. 2021, 28(2), 1366–1375; https://doi.org/10.3390/curroncol28020130
Available online: https://www.mdpi.com/1718-7729/28/2/130

10. “Extent of Groin Dissection in Melanoma: A Mixed-Methods, Population-Based Study of Practice Patterns and Outcomes”
by Suzana Küpper, Janice L. Austin, Brittany Dingley, Yuan Xu, Kristine Kong, Mantaj Brar, Frances C. Wright, Carolyn Nessim, Antoine Bouchard-Fortier and May Lynn Quan
Curr. Oncol. 2021, 28(6), 5422–5433; https://doi.org/10.3390/curroncol28060452
Available online: https://www.mdpi.com/1718-7729/28/6/452

Back to TopTop